Session » Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2550

A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)

9:00AM-11:00AM: Abstract Number: 2549

Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2543

Agreement between Paper and Pencil VAS at the Clinic and Electronic VAS at Home in Psoriatic Arthritis and Its Impact on Minimal Disease Activity

9:00AM-11:00AM: Abstract Number: 2529

Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2500

Are Work Outcomes Improved in Axial Spondyloarthritis (axSpA) Patients with Biologic Therapy? Results from the British Society for Rheumatology Register

9:00AM-11:00AM: Abstract Number: 2526

Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology

9:00AM-11:00AM: Abstract Number: 2545

Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Two-Year Prospective Cohort Study in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2538

Change in Self-Reported Health Status and Fatigue before and after the Diagnosis of Psoriatic Arthritis- the Nord-Trondelag Health Study (HUNT)

9:00AM-11:00AM: Abstract Number: 2537

Changes in Severity, Functional Status, and Wellbeing over Time Among Individuals with Ankylosing Spondylitis (AS) in Canada: Results from the RHUMADATA® Multicentre Registry

9:00AM-11:00AM: Abstract Number: 2519

Characteristics of Eye Diseases in Patients with Ankylosing Spondylitis in Korea: A Single-Center Survey

9:00AM-11:00AM: Abstract Number: 2555

Clinical History of Psoriatic Arthritis over Four Decades

9:00AM-11:00AM: Abstract Number: 2530

Clinical Specialty Setting As a Determinant for Disease Management in Patients with Psoriatic Arthritis: An Interim Analysis of the Cross-Sectional Observational Study

9:00AM-11:00AM: Abstract Number: 2551

Comparison between Two Cut-Off Values of Disease Activity in Psoriatic Arthritis Index and Validation of Its Simplified Clinical Version in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2536

Comparison of Quality-of-Life, Function and Psoriasis Measures in Minimal Disease Activity and DAS28 States in Routine Care of Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2533

Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity

9:00AM-11:00AM: Abstract Number: 2507

Dactylitis and Enthesitis Predict Uveitis in Large Axial Spondyloarthropathy Cohort

9:00AM-11:00AM: Abstract Number: 2502

Defining Clinically Important Worsening Based on ASDAS-CRP for Axial Spondyloarthritis: A Data-Based Consensus By the Assessment in Spondyloarthritis International Society (ASAS)

9:00AM-11:00AM: Abstract Number: 2554

Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available

9:00AM-11:00AM: Abstract Number: 2557

Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not?

9:00AM-11:00AM: Abstract Number: 2503

Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?

9:00AM-11:00AM: Abstract Number: 2499

Gender Differences in Axial and Peripheral Spondyloarthritis: Results from the Esperanza Cohort

9:00AM-11:00AM: Abstract Number: 2509

High Prevalence of Sarcopenia in Axial Spondyloarthropathy Cohort

9:00AM-11:00AM: Abstract Number: 2512

Impact of Inflammatory Bowel Disease in Early Spondyloarthritis in a Prospective Longitudinal Cohort

9:00AM-11:00AM: Abstract Number: 2540

Impact of Sleep on Measures of Disease Activity in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2506

In Ankylosing Spondylitis/Axial Spondyloarthritis Smoking Is Associated with a Dose Related Elevation in CRP, Worse Disease Activity and Worse Quality of Life over One Year

9:00AM-11:00AM: Abstract Number: 2520

Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World

9:00AM-11:00AM: Abstract Number: 2527

Increased Prevalence of Subclinical Atherosclerosis in Moderate-Severe Plaque Psoriasis Patients

9:00AM-11:00AM: Abstract Number: 2525

Influence of Cardiovascular Comorbidity on Achieving Therapeutic Goals: A Comparative Study between Recent-Onset Psoriatic Arthritis and Established Disease

9:00AM-11:00AM: Abstract Number: 2552

Inter-Connections between Fatigue, Pain and Patient Global Assessement in Patients with Active Spondyloarthritis Followed in the Daily Clinic

9:00AM-11:00AM: Abstract Number: 2511

Irritable Bowel Syndrome and Its Impact on Patient-Reported Outcomes in Axial Spondyloarthritis: Is It an Overlooked Comorbidity?

9:00AM-11:00AM: Abstract Number: 2542

Measuring Psoriasis Specific Impact on Quality of Life: Performance of Dlqi and Skindex-17 in Early Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2521

Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes

9:00AM-11:00AM: Abstract Number: 2522

Metabolic Syndrome, NAFLD and LIVER Stiffness in Psoriatic Arthritis and Psoriasis Patients: A CROSS-Sectional Study

9:00AM-11:00AM: Abstract Number: 2508

Obese Axial Spondyloarthropathy Patients Have Worse Disease Outcomes

9:00AM-11:00AM: Abstract Number: 2553

Patient and Physician Global Assessment Are Poorly Inter-Connected and Poorly Explained By Other Clinical Markers of Disease Activity in Individual Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2535

Patient Outcomes from a Tertiary Center Combined Rheumatology-Dermatology Clinic

9:00AM-11:00AM: Abstract Number: 2501

Potential Differences in Axial Spondyloarthritis Disease Activity Categorization Using Different Minimum Values for High-Sensitivity CRP in Ankylosing Spondylitis Disease Activity Score Calculation and Different Definitions of Disease Flare

9:00AM-11:00AM: Abstract Number: 2515

Prevalence and Risk Factors for Osteoporotic Fractures and Low Bone Mineral Density in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2510

Prevalence of and Factors Associated with Sarcopenia in Patients of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2528

Prevalence of Depression and Attention Deficit Hyperactivity Disorder in Female Patients at a Combined Psoriasis-Psoriatic Arthritis Center

9:00AM-11:00AM: Abstract Number: 2544

Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact

9:00AM-11:00AM: Abstract Number: 2518

Racial Differences in Clinical Characteristics and Co-Morbidities of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2498

Rheumatologists Use Different Cut-Offs for Disease Activity in Real Life – the Experience with Golimumab in Ankylosing Spondylitis- Subanalysis from a Non-Interventional German Study

9:00AM-11:00AM: Abstract Number: 2546

Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2539

The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2496

The Disease Course in Daily Clinical Practice in Radiographic and Non-Radiographic Axial Spondyloarthritis Patients; One-Year Follow-up Results of National-Subgroup of a Worldwide Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 2513

The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2547

the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort

9:00AM-11:00AM: Abstract Number: 2523

The Prevalence, Incidence and Associated Factors for Liver Abnormalities in Psoriatic Arthritis: Resutls from a Longitudinal Observational Cohort

9:00AM-11:00AM: Abstract Number: 2534

the Relationship between Biological Therapy, Work Productivity, and Activity Impairment in Patients with Psoriatic Arthritis: Prospective Multicentre Observational Study

9:00AM-11:00AM: Abstract Number: 2532

The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry

9:00AM-11:00AM: Abstract Number: 2541

The Relationship between the Patient Acceptable Symptom State (PASS) and Disease Activity in Patients with Psoriatic Arthritis (PsA)

9:00AM-11:00AM: Abstract Number: 2497

The Role of Individual and Country-Level Socio-Economic Factors in Work Participation in Patients with Spondyloarthritis across 22 Countries Worldwide: Results from the Comospa Study

9:00AM-11:00AM: Abstract Number: 2517

The Usefulness of Trabecular Bone Score in Assessing the Bone Strength and Fracture Risk of Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2504

The Validation of Istanbul Back Disability Index (IBDI) in Axial Spondyloarthritis Patients

9:00AM-11:00AM: Abstract Number: 2516

Trabecular Bone Score As an Assessment Tool to Identify the Risk of Osteoporosis in Axial Spondyloarthritis: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 2505

Trends in Time to Diagnosis in Spondyloarthritis Patients. Association with 2009 ASAS Classification Criteria and Clinical Presentation at Disease Onset. Data from Comospa Study

9:00AM-11:00AM: Abstract Number: 2531

Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry

9:00AM-11:00AM: Abstract Number: 2548

Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab

9:00AM-11:00AM: Abstract Number: 2524

Weight Change before and after Diagnosis in Patients with Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2556

Were Moll and Wright Right?

9:00AM-11:00AM: Abstract Number: 2514

When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].